<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02548611</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE MucT002-14</org_study_id>
    <nct_id>NCT02548611</nct_id>
  </id_info>
  <brief_title>Comparison of Loading Strategies With Antiplatelet Drugs in Patients Undergoing Elective Coronary Intervention</brief_title>
  <acronym>SASSICAIA</acronym>
  <official_title>Intensified Loading With Prasugrel Versus Standard Loading With Clopidogrel in Invasive-treated Patients With Biomarker-Negative Angina Pectoris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LMU Klinikum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LMU Klinikum</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Use of high loading doses of clopidogrel (antiplatelet drug) just before coronary&#xD;
      interventions is associated with improved outcomes after coronary stenting. However the onset&#xD;
      of platelet inhibition after clopidogrel loading takes 2 to 4 hours and its action if very&#xD;
      variable. A way to overcome this limitation is loading with a more potent antiplatelet drug&#xD;
      such as prasugrel. Therefore in the current study the investigators want to compare loading&#xD;
      with 60 mg prasugrel (potent antiplatelet drug) and loading with clopidogrel (standard drug)&#xD;
      in patients undergoing elective coronary intervention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with stable or clinically unstable (biomarker-negative) angina pectoris who are in&#xD;
      need of coronary intervention will be randomly assigned in one of the treatment strategies -&#xD;
      60 mg of prasugrel or 600 mg clopidogrel just prior to percutaneous coronary intervention&#xD;
      (PCI). After PCI all patients will receive clopidogrel 75 mg/d as per standard. The patients&#xD;
      will be monitored throughout a 30-day time frame and ischemic and bleeding events will be&#xD;
      recorded. The study is powered to show the superiority of single-dose 60 mg prasugrel over&#xD;
      single-dose 600 mg clopidogrel regarding the ischemic complications at 30-day follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to low recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Actual">November 2018</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined ischemic events</measure>
    <time_frame>30 days</time_frame>
    <description>Combined outcome of all-cause death, any myocardial infarction (MI), stent thrombosis, urgent revascularization and stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>Academic Research Consortium ≥2 bleeding and TIMI classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peri-PCI MI Type 4a</measure>
    <time_frame>30 days</time_frame>
    <description>according to Third Universal Definition of MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>30 days</time_frame>
    <description>mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any myocardial infarction</measure>
    <time_frame>30 days</time_frame>
    <description>according to SASSICAIA protocol definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>30 days</time_frame>
    <description>according to Academic Research Consortium criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urgent vessel revascularization</measure>
    <time_frame>30 days</time_frame>
    <description>revascularization related to symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cerebro-vascular events</measure>
    <time_frame>30 days</time_frame>
    <description>stroke and TIA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">795</enrollment>
  <condition>Angina Pectoris</condition>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single-dose loading with 60 mg of prasugrel pre PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>loading with 600 mg of clopidogrel pre PCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>see arm description</description>
    <arm_group_label>Prasugrel</arm_group_label>
    <other_name>Efient</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>see arm description</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <other_name>Iscover, Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with biomarker negative stable or unstable angina pectoris&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  In women with childbearing potential a pregnancy test is obligatory&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years and &gt;80 years&#xD;
&#xD;
          -  ST-elevation MI&#xD;
&#xD;
          -  Elevated cardiac biomarkers&#xD;
&#xD;
          -  Subjects with known contraindications to clopidogrel treatment, which are&#xD;
             hypersensitivity to the drug substance or any component of the product and active&#xD;
             pathological bleeding such as peptic ulcer or intracranial hemorrhage and with known&#xD;
             severe liver disease (Child Pugh Class C)&#xD;
&#xD;
          -  Subjects with known contraindications to prasugrel treatment, which are&#xD;
             hypersensitivity to the drug substance or any component of the product, active&#xD;
             pathological bleeding such as peptic ulcer or intracranial hemorrhage and a history of&#xD;
             prior transient ischemic attack (TIA) or stroke and with known severe liver disease&#xD;
             (Child Pugh Class C)&#xD;
&#xD;
          -  Chronic therapy on potent P2Y12 receptor inhibitors (ticagrelor, prasugrel)&#xD;
&#xD;
          -  Pre-treatment with a loading dose of either clopidogrel, prasugrel or ticagrelor&#xD;
&#xD;
          -  Simultaneous participation in another clinical trial that involves the administration&#xD;
             of an investigational medicinal drug within 30 days prior to the start of this&#xD;
             clinical trial&#xD;
&#xD;
          -  Major surgeries in the last 6 weeks and planned surgeries within the next 6 weeks (per&#xD;
             decision of the treating physician)&#xD;
&#xD;
          -  Active bleeding&#xD;
&#xD;
          -  Known or persistent abuse of medication, drugs or alcohol&#xD;
&#xD;
          -  Current or planned pregnancy or nursing women, women 90 days after childbirth. Females&#xD;
             of childbearing potential, who do not use and are not willing to use medically&#xD;
             reliable methods of contraception for the entire study duration (such as oral,&#xD;
             injectable, or implantable contraceptives, or intrauterine contraceptive devices)&#xD;
             unless they are surgically sterilized / hysterectomized or there are any other&#xD;
             criteria considered sufficiently reliable by the investigator in individual cases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julinda Mehilli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitäts-Herzzentrum Freiburg, Bad Krozingen</name>
      <address>
        <city>Freiburg</city>
        <state>Bad Krozingen</state>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Munich University Hospital</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bogenhausen</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Center Balatonfüred and Heart and Vascular Center</name>
      <address>
        <city>Balatonfüred</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
  </location_countries>
  <link>
    <url>https://www.ahajournals.org/doi/full/10.1161/CIRCINTERVENTIONS.119.008649?url_ver=Z39.88-2003&amp;rfr_id=ori%3Arid%3Acrossref.org&amp;rfr_dat=cr_pub++0pubmed&amp;</url>
    <description>Study result publication</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 10, 2015</study_first_submitted>
  <study_first_submitted_qc>September 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2015</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>LMU Klinikum</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Julinda Mehilli</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

